March 23, 2025
Financière de Tubize – Annual report 2024
Annual Report 2024Regulated information 22 March 2025 The board of directors of Financière de Tubize has established the 2024 annual…
Pharmaceuticals, Biotechnology and Life Sciences
Annual Report 2024Regulated information 22 March 2025 The board of directors of Financière de Tubize has established the 2024 annual…
AURORA, Colo., March 22, 2025 (GLOBE NEWSWIRE) — Arialief is a unique nerve pain and discomfort relief supplement with natural…
Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab…
No Shareholder Action is Required at this TimeBOSTON, March 21, 2025 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea…
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)…
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) — The attached notifications relate to trades entered into by a PDMR of…
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes…
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130…
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for…
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming…